🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06316895
Recruiting Observational

The Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma

NCT06316895 · tracked via the Priya Life Science China tracker
Sponsor
Chinese PLA General Hospital
Phase
Observational
Started
2024-04-01
Last updated
2026-03-20

Condition(s) studied

Papillary Thyroid Cancer

Investigational drug(s) / intervention(s)

thyroid surgeryultrasound-guided thermal ablation

thyroid surgery: thyroid lobectomy

ultrasound-guided thermal ablation: radiofrequency ablation; microwave ablation or laser ablation

Study summary

1. To evaluate the clinical outcomes of ultrasound-guided thermal ablation and thyroid surgery for the treatment of papillary thyroid carcinoma;
2. To develop and validate a artificial intelligence model to predict the outcomes of ultrasound-guided thermal ablation in the treatment of papillary thyroid carcinoma;

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. patients age between 18 and 80 year old, both sex 2. papillary thyroid carcinoma confirmed by core-needle biopsy or fine-needle aspiration 3. the largest diameter ≤2.0 cm 4. no clinical or imaging evidences of extrathyroidal extension, lymph node metastasis and distant metastasis on ultrasound, nech and chest CT 5. follow-up period ≥12 months, Exclusion Criteria: 1. patients with convincing evidence of aggressive papillary thyroid carcinoma or other type of thyroid cancer by biopsy 2. history of neck radiation 3. history of thyroid surgery 4. coagulation disorder 5. serious heart, respiratory, liver, or renal failure 6. dysfunction of the vocal cord on the opposite side

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Chinese PLA General Hospital Beijing China Recruiting

More Chinese PLA General Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06316895 on ClinicalTrials.gov ↗ ← All trials in China